MDS research criteria for prodromal Parkinson's disease.
about
Emerging approaches in Parkinson's disease - adjunctive role of safinamideRepurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's diseaseThe prediagnostic phase of Parkinson's diseaseOptimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's diseaseEnvironmental Exposures and Parkinson's DiseaseUsefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes.Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT scoreAutomated analysis of connected speech reveals early biomarkers of Parkinson's disease in patients with rapid eye movement sleep behaviour disorderThe gut microbiome in human neurological disease: A review.Non-motor symptoms and quality of life in subjects with mild parkinsonian signs.Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.Striatal and Hippocampal Atrophy in Idiopathic Parkinson's Disease Patients without Dementia: A Morphometric Analysis.Neuroimaging in pre-motor Parkinson's diseaseClinical Application of Brain MRI in the Diagnostic Work-up of Parkinsonism.Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effectsImaging Parkinson's disease below the neck.Co-morbidity and polypharmacy in Parkinson's disease: insights from a large Scottish primary care database.Downregulation of blood serum microRNA 29 family in patients with Parkinson's diseaseMDS clinical diagnostic criteria for Parkinson's disease.Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease.Recent advances in treating Parkinson's disease.Odor Identification Test in Idiopathic REM-Behavior Disorder and Parkinson's Disease in ChinaDaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers."Gunslinger's gait": a new cause of unilaterally reduced arm swing.Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.Inflammatory profile in LRRK2-associated prodromal and clinical PDTrait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease?Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection.Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology.Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.Natural history of pure autonomic failure: A United States prospective cohortPREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.Associations between Early Markers of Parkinson's Disease and Sarcopenia.The Synucleinopathies: Twenty Years On.Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinson's DiseaseAlterations in striato-thalamo-pallidal intrinsic functional connectivity as a prodrome of Parkinson's disease.The Concept of Prodromal Parkinson's Disease.Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD.
P2860
Q26740905-5AC2D897-1386-450B-8C34-9C13D8C37941Q26748711-CB8226E5-CA38-460B-8A43-58F09015BBB9Q26768732-B875B746-19C1-4DE7-8088-CB4ED2CA8670Q28071861-0002DA07-008E-471F-BB56-9E121886084BQ28074723-091F3B54-F235-4A57-943B-3743C9F6BB68Q28553194-7E3B2EC8-0614-461B-BC6B-47D3E4E09495Q29048624-FC5C827D-3E30-4BB6-864E-02C8877187CEQ30356478-82CC6057-2DFA-4B04-8F3E-3985D33CD0E8Q30490923-E8CC7A45-060A-4716-B25B-C9879AEC1E41Q30572455-6484F6AC-3D2E-445A-8413-F830FBB9D6DEQ30841744-A865493A-5F4E-4FAE-97D7-3683DDDBAE4CQ33559200-0E5DC4BC-6A19-44DB-B186-8412640010CDQ33676222-FE04A638-A9F0-458B-9F2A-C35C871A619EQ33708957-4C40A4D5-D59F-4136-960C-6C91A51D00F5Q33731267-82A94038-4DCB-4B56-9CAA-E245A4FE7ADEQ33734084-2AC761F4-2976-4B70-BB08-CE6E0440F909Q33767061-FB1DC077-3DBC-448D-9DBE-B83DCF43B6A7Q33861898-04BA9B58-34D4-44BD-957C-2FAEA644404CQ33905821-FB93297C-D5EF-4CB1-B9A5-0E3F0D04F657Q34498274-504C1348-B8EA-44C4-A40F-07B2CA403898Q34550489-02BA0334-58D0-447C-92E7-89BF5EB22AB6Q34554401-49D56AF4-DF18-4808-845F-91EBBA3109E6Q36092538-84D0956B-53F3-4A6E-A602-4FEF4C96F2A5Q36345908-38C52000-BB2D-4399-A4CD-C1B1CE5749B8Q36369299-81734E16-B621-406B-A2B1-13FABFAF6B94Q36374541-06AB1AAB-D1BD-46C7-ACD4-5D9A1A162F6CQ36934387-CEEA9B07-4E98-49AB-9AAC-DFB9B44612E5Q36946063-2B953125-60DA-4F99-BF14-1AD484A262E4Q37054007-FA1604AE-602D-436A-BF47-F2FEBBB3F21CQ37129119-695E9753-34A7-4183-B1A8-2A21F57082F4Q37548320-5BE81A5D-06E1-4DF8-9C52-7D22FAA3BB1FQ37662455-92634710-06F7-476D-A92D-D8CAA0F4F7E0Q37663889-B7DF4C9E-7C9D-4386-9F7D-C2352857C38AQ37683074-17D232BD-2599-4AC0-B597-3336F7931D65Q37693375-131C4C9F-3094-4E83-AE57-0EF93285DC8DQ38384109-6E5950CB-107B-43E9-9AAE-F690C64F1A22Q38601317-18117586-844A-4E9C-B707-ADF72C1B191FQ38612230-422E8D8C-37FD-44FD-A5EF-9A4DF37D8078Q38666247-A4CB2EFD-7A7B-4B49-9D8D-798D4CA51216Q38702118-5AF40D2D-B14C-4517-A495-638F4C7A692C
P2860
MDS research criteria for prodromal Parkinson's disease.
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
MDS research criteria for prodromal Parkinson's disease.
@ast
MDS research criteria for prodromal Parkinson's disease.
@en
MDS research criteria for prodromal Parkinson's disease.
@nl
type
label
MDS research criteria for prodromal Parkinson's disease.
@ast
MDS research criteria for prodromal Parkinson's disease.
@en
MDS research criteria for prodromal Parkinson's disease.
@nl
prefLabel
MDS research criteria for prodromal Parkinson's disease.
@ast
MDS research criteria for prodromal Parkinson's disease.
@en
MDS research criteria for prodromal Parkinson's disease.
@nl
P2093
P2860
P50
P356
P1433
P1476
MDS research criteria for prodromal Parkinson's disease.
@en
P2093
José Obeso
Kenneth Marek
Lawrence Joseph
Matthew Stern
Ronald B Postuma
P2860
P304
P356
10.1002/MDS.26431
P407
P50
P577
2015-10-01T00:00:00Z